MATERIALS AND METHODS
NSCLC
DISEASE PROGRESSION, NSCLC
This was a multicenter, open‐label Phase 1 study of DS‐1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR‐mutant NSCLC and disease progression during treatment with one or more EGFR‐TKIs (gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib). The study was registered at 